Refine by
Clinical Trial Support Articles & Analysis: Older
230 news found
Protheragen-ING Lab, a well-known and reputable Good Laboratory Practices (GLP) service provider, has recently unveiled its cutting-edge medical device services. With a track record of excellence and reliability in providing high-quality services to the pharmaceutical and biotechnology industries, Protheragen-ING Lab is now expanding its offerings to include comprehensive solutions for medical ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
Ingredients for muscle mass and post-workout recovery remain mainstays in sports nutrition, but the category is evolving and broadening. Ingredient examples are phospholipids for cognition and probiotic cultures for digestive health. “It’s very well-known that health is increasingly perceived holistically by consumers, especially younger demographics,” said Paige Wilkinson, ...
It is a well-respected heart health research institute, which also participates in clinical trials targeting new ways to manage, prevent and cure cardiovascular disease. ...
For nearly 16 years, she worked for CureVac, the global biopharmaceutical company and took responsibility as Chief Scientific and Chief Technology Officer. Her revolutionary work has supported multiple clinical trials with cancer therapies, prophylactic vaccines, and development of antibody therapies. ...
ByArdigen
The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. ...
Destiny Pharma will continue to work with NIAID to complete this preclinical safety package which will support future clinical development of XF-73 Dermal in serious wound infections. The study is planned to complete in Q2 2023 and should then be ready to move into clinical trials. Neil Clark, CEO of Destiny Pharma, said: ...
BOC Sciences, as a professional contract research organization, can take care of the PROTAC in vivo evaluation workload for clients with a transparent project process and comprehensive evaluation reports to facilitate their PROTAC discovery and development programs prior to clinical trials. According to the classification of drugs and the characteristics of ...
“We are pleased that Cingulate has trusted Societal CDMO to carry out these essential activities to support CTx-1301 at such a critical juncture on its path through clinical development and toward ...
AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of ...
NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study, supporting its precision medicine approach to the diagnosis and treatment of autism spectrum disorder (ASD) at the National TACA Autism Conference. ...
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA-cleared, clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis and a patented intuitive display of contextual patient data for more efficient, actionable clinical decisions. As part of the recently ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Effective October 3rd, 2022, Laurie Smith has joined as Vice President of Product Strategy – Clinical Trial Matching. Laurie will be primarily focused on enhancing Inspirata’s suite of clinical trial matching solutions. ...
Award to support Phase 1b studies to evaluate tau self-association small molecule inhibitor In August, company announced a $3.35M grant from NIH to support a Phase 1a clinical trial Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative ...
Signifier Medical Technologies is supporting four clinical trials on these topics, currently underway. Signifier is a pioneer in addressing a key root cause of sleep disordered breathing. ...
The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. ...
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained a solid reputation. Recently, Creative Enzymes launched a variety of ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. ...
The first patient’s data from the RESKUE clinical trial demonstrate that intravenous FBX-101 following UCBT has been safe and well tolerated through Day 180. ...